Integrity of 111In-radiolabeled superparamagnetic iron oxide nanoparticles in the mouse

Wang, Haotian; Kumar, Rajiv; Nagesha, Dattatri; Duclos, R.; Sridhar, Srinivas; Gatley, S. John

doi:10.1016/j.nucmedbio.2014.08.014

Cited by 49 publications

(43 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The bio-distribution studies showed that despite detection of 111 In in reticuloendothelial organs, 59 Fe analysis showed a greater level than 111 In in liver and spleen, while analysis of 14 C demonstrated lower levels. 97 …”

Section: Radiolabeled Mnpsmentioning

confidence: 99%

Radiolabeled theranostics: magnetic and gold nanoparticles

et al. 2016

View full text Add to dashboard Cite

Introduction: Growing advances in nanotechnology have facilitated the applications of newly emerged nanomaterials in the field of biomedical/pharmaceutical sciences. Following this trend, the multifunctional nanoparticles (NPs) play a significant role in development of advanced drug delivery systems (DDSs) such as diapeutics/theranostics used for simultaneous diagnosis and therapy. Multifunctional radiolabeled NPs with capability of detecting, visualizing and destroying diseased cells with least side effects have been considered as an emerging filed in presentation of the best choice in solving the therapeutic problems. Functionalized magnetic and gold NPs (MNPs and GNPs, respectively) have produced the potential of nanoparticles as sensitive multifunctional probes for molecular imaging, photothermal therapy and drug delivery and targeting. Methods: In this study, we review the most recent works on the improvement of various techniques for development of radiolabeled magnetic and gold nanoprobes, and discuss the methods for targeted imaging and therapies. Results: The receptor-specific radiopharmaceuticals have been developed to localized radiotherapy in disease sites. Application of advanced multimodal imaging methods and related modality imaging agents labeled with various radioisotopes (e.g., 125I, 111In, 64Cu, 68Ga, 99mTc) and MNPs/GNPs have significant effects on treatment and prognosis of cancer therapy. In addition, the surface modification with biocompatible polymer such as polyethylene glycol (PEG) have resulted in development of stealth NPs that can evade the opsonization and immune clearance. These long-circulating agents can be decorated with homing agents as well as radioisotopes for targeted imaging and therapy purposes. Conclusion: The modified MNPs or GNPs have wide applications in concurrent diagnosis and therapy of various malignancies. Once armed with radioisotopes, these nanosystems (NSs) can be exploited for combined multimodality imaging with photothermal/photodynamic therapy while delivering the loaded drugs or genes to the targeted cells/tissues. These NSs will be a game changer in combating various cancers.

show abstract

Section: Radiolabeled Mnpsmentioning

confidence: 99%

Radiolabeled theranostics: magnetic and gold nanoparticles

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In three of the studies, we found approximately equal liver uptake 24 hours after administration (43)(44)(45). The large accumulation in the liver is because of scavenging and phagocytosis by cellular elements of the RES.…”

Section: Liver Uptakementioning

confidence: 61%

Dual nano‐sized contrast agents in PET/MRI: a systematic review

Lahooti

Sarkar

Laurent

et al. 2016

Contrast Media & Molecular

View full text Add to dashboard Cite

Nowadays molecular imaging plays a vital role in achieving a successful targeted and personalized treatment. Hence, the approach of combining two or more medical imaging modalities was developed. The objective of this review is to systematically compare recent dual contrast agents in Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) and in some cases Single photon emission computed tomography (SPECT)/MRI in terms of some their characteristics, such as tumor uptake, and reticuloendothelial system uptake (especially liver) and their relaxivity rates for early detection of primary cancer tumor. To the best of our knowledge, this is the first systematic and integrated overview of this field. Two reviewers individually directed the systematic review search using PubMed, MEDLINE and Google Scholar. Two other reviewers directed quality assessment, using the criteria checklist from the CAMARADES (Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies) tool, and differences were resolved by consensus. After reviewing all 49 studies, we concluded that a size range of 20-200 nm can be used for molecular imaging, although it is better to try to achieve as small a size as it is possible. Also, small nanoparticles with a hydrophilic coating and positive charge are suitable as a T contrast agent. According to our selected data, the most successful dual probes in terms of high targeting were with an average size of 40 nm, PEGylated using peptides as a biomarker and radiolabeled with copper 64 and gallium 68. Copyright © 2017 John Wiley & Sons, Ltd.

show abstract

“…SPIONs have been labeled with multiple radioisotopes for both SPECT ( 99m Tc [231, 232], 125 I [233], 111 I [234, 235], 125 I [236] and 131 I [237, 238]) and PET. [239] Traditional approach involving chelating agents such as DOTA [240–243], NOTA [204, 244, 245], DTPA [246] and bis(dithiocarbamatebisphosphonate) (DTCPB) [247, 248] for 64 Cu and 68 Ga, and DFO for 89 Zr [249] has been reported in an array of differently designed and surface-functionalized SPIONs.…”

Section: Radiolabeled Nanomaterials For Cancer Theranosticsmentioning

confidence: 99%

Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics

Goel

England

Chen

et al. 2017

Advanced Drug Delivery Reviews

159

104

View full text Add to dashboard Cite

Development of novel imaging probes for cancer diagnosis is critical for early disease detection and management. The past two decades have witnessed a surge in the development and evolution of radiolabeled nanoparticles as a new frontier in personalized cancer nanomedicine. The dynamic synergism of positron emission tomography (PET) and nanotechnology combines the sensitivity and quantitative nature of PET with the multifunctionality and tunability of nanomaterials, which can help overcome certain key challenges in the field. In this review, we discuss the recent advances in radionanomedicine, exemplifying the ability to tailor the physicochemical properties of nanomaterials to achieve optimal in vivo pharmacokinetics and targeted molecular imaging in living subjects. Innovations in development of facile and robust radiolabeling strategies and biomedical applications of such radionanoprobes in cancer theranostics are highlighted. Imminent issues in clinical translation of radiolabeled nanomaterials are also discussed, with emphasis on multidisciplinary efforts needed to quickly move these promising agents from bench to bedside.

show abstract

Integrity of 111In-radiolabeled superparamagnetic iron oxide nanoparticles in the mouse

Cited by 49 publications

References 23 publications

Radiolabeled theranostics: magnetic and gold nanoparticles

Radiolabeled theranostics: magnetic and gold nanoparticles

Dual nano‐sized contrast agents in PET/MRI: a systematic review

Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics

Contact Info

Product

Resources

About